Research conducted at the University Hospital in Bern, Switzerland suggests that scleral changes may occur in patients following repeated intravitreal injections of anti-VEGF agents in the same quadrant.
Retina India is a not-for-profit organization, registered with the Charity Commissioner, Mumbai, India, established for empowering people with retinal disorders, and bringing them and their families on a common platform with physicians, researchers, counselors, low vision and mobility experts and other specialists.
Showing posts with label Eylea. Show all posts
Showing posts with label Eylea. Show all posts
Thursday, April 23, 2015
Scleral thinning seen following intravitreal anti-VEGF injections
Research conducted at the University Hospital in Bern, Switzerland suggests that scleral changes may occur in patients following repeated intravitreal injections of anti-VEGF agents in the same quadrant.
Friday, September 19, 2014
EYLEA (aflibercept) injection receives FDA breakthrough therapy designation for diabetic retinopathy in patients with diabetic macular edema
Regeneron Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Eylea® (aflibercept) injection a breakthrough therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). The designation is based on positive results in two Phase 3 trials (VIVID-DME and VISTA-DME), in which Eylea demonstrated a statistically significant improvement
in a pre-specified measure of diabetic retinopathy in patients with DME after two years of treatment.
Subscribe to:
Posts (Atom)